Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.

Tortorici MA, Cutler DL, Hazra A, Nolin TD, Rowland-Yeo K, Venkatakrishnan K.

J Clin Pharmacol. 2014 Dec 11. doi: 10.1002/jcph.444. [Epub ahead of print]

PMID:
25501531
2.

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

Chen X, Kosoglou T, Statkevich P, Kumar B, Li J, Dockendorf MF, Wang G, Lowe RS, Jiang J, Liu H, Wang Z, Cutler DL, Hu P.

Int J Clin Pharmacol Ther. 2014 Oct;52(10):889-99. doi: 10.5414/CP202121.

PMID:
25138682
3.

Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.

Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS, Kim K, Miller SD.

Chest. 2013 Dec;144(6):1795-802. doi: 10.1378/chest.13-0505.

PMID:
24077095
4.

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Wang Z, Xuan F, Lin WH, Troyer MD, Tendolkar A, Cutler DL.

Eur J Clin Pharmacol. 2013 Oct;69(10):1761-7. doi: 10.1007/s00228-013-1541-5. Epub 2013 Jul 16.

PMID:
23857248
5.
6.

The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.

Kosoglou T, Statkevich P, Kumar B, Xuan F, Schiller JE, Johnson-Levonas AO, Young S, Cutler DL.

J Clin Pharmacol. 2013 May;53(5):540-9. doi: 10.1002/jcph.20. Epub 2013 Feb 20.

PMID:
23426761
7.

Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects.

Cutler DL, Tendolkar A, Grachev ID.

J Clin Pharm Ther. 2012 Oct;37(5):578-87. doi: 10.1111/j.1365-2710.2012.01349.x. Epub 2012 Jun 7.

PMID:
22676397
8.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.

Statkevich P, Kosoglou T, Preston RA, Kumar B, Xuan F, Trusley C, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1501-8. doi: 10.1007/s00228-012-1269-7. Epub 2012 Apr 19.

PMID:
22527342
9.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Kosoglou T, Zhu Y, Xuan F, Black L, Johnson-Levonas AO, Martinho M, Statkevich P, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1509-16. doi: 10.1007/s00228-012-1271-0. Epub 2012 Apr 5.

PMID:
22476387
10.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Jul;68(7):1049-56. doi: 10.1007/s00228-012-1217-6. Epub 2012 Feb 8.

PMID:
22315147
11.

Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects.

Cutler DL, Tendolkar A, Grachev ID.

J Clin Pharmacol. 2012 Nov;52(11):1698-703. doi: 10.1177/0091270011428321. Epub 2011 Dec 13.

PMID:
22167566
12.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.

Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912.

13.

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.

Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL.

Eur J Clin Pharmacol. 2012 Mar;68(3):291-300. doi: 10.1007/s00228-011-1127-z. Epub 2011 Oct 4.

PMID:
21969227
14.

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects.

Kosoglou T, Reyderman L, Tiessen RG, van Vliet AA, Fales RR, Keller R, Yang B, Cutler DL.

Eur J Clin Pharmacol. 2012 Mar;68(3):249-58. doi: 10.1007/s00228-011-1120-6. Epub 2011 Sep 21.

PMID:
21935705
15.

Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

Gupta SK, Kolz K, Cutler DL.

Eur J Clin Pharmacol. 2011 Jun;67(6):591-9. doi: 10.1007/s00228-010-0972-5. Epub 2010 Dec 16.

PMID:
21161196
16.

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.

Kosoglou T, Zhu Y, Statkevich P, Triantafyllou I, Taggart W, Xuan F, Kim KT, Cutler DL.

Eur J Clin Pharmacol. 2011 May;67(5):483-92. doi: 10.1007/s00228-010-0955-6. Epub 2010 Dec 1.

PMID:
21120461
17.

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.

Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI.

Cancer Chemother Pharmacol. 2011 Feb;67(2):455-63. doi: 10.1007/s00280-010-1488-5. Epub 2010 Oct 24.

PMID:
20972873
18.

Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis.

Kosoglou T, Cutler DL, Staudinger H, Herron JM.

Chest. 2010 Jan;137(1):115-21. doi: 10.1378/chest.09-0235. Epub 2009 Sep 11.

PMID:
19749003
19.

Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

Zhu Y, Statkevich P, Cutler DL.

Int J Clin Pharmacol Ther. 2007 Oct;45(10):539-47.

PMID:
17966839
20.

Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.

Gupta SK, Swan SK, Marbury T, Smith W, Schwartz S, Kolz K, Cutler DL.

Br J Clin Pharmacol. 2007 Dec;64(6):726-32. Epub 2007 Jun 6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk